Drugs / AGuIX
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03308604 | May 2018 → Jul 2022 | female reproductive organ cancer | Gustave Roussy, Cancer Campus, Grand Paris | Unknown | No outcome recorded |
| Phase 1 | NCT02820454 | Mar 2016 → Feb 2019 | metastatic malignant neoplasm in the brain | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04881032 | Mar 2022 → Sep 2025 overdue | glioblastoma | Centre Jean Perrin | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04789486 | May 2021 → Apr 2028 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04899908 | Sep 2021 → Apr 2028 expected | HER2 positive breast carcinoma, colorectal cancer, lung cancer, melanoma +1 | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04094077 | Jan 2020 → Feb 2021 | metastatic malignant neoplasm in the brain | Centre Leon Berard | Terminated | No outcome recorded |
| Phase 2 | NCT03818386 | Mar 2019 → Jun 2024 | metastatic malignant neoplasm in the brain | University Hospital, Grenoble | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGUIX | “This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in...” NCT04789486 ↗ |
| Known as | Activation and Guidance of Irradiation X | “This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in...” NCT04789486 ↗ |
| Modality | Other / unclassified | “A gadolinium-based nanoparticle, AGuIX, has recently demonstrated its effectiveness as theranostic and radiosensitiser agent” PMID 30755445 ↗ Feb 2019 |
| Route | Intravenous | “patients will receive a single intravenous injection of AGuIX” NCT02820454 ↗ |